N 1–2 (179–180) 2022. P. 92–95

EXPERIENCE OF PRIMARY HPV TESTING IN CERVICAL CANCER SCREENING

O. V. Bondar, A. I. Rybin, V. V. Muzyka

Odesa National Medical University , Odesa, Ukraine

DOI 10.54229/2226-2008-2022-1-2-16

The main cause of cervical cancer in almost 100% of cases is the human papillomavirus (HPV), which is also involved in the development of other cancers of the lower genital tract. The malignant transformation of the cervical epithelium is a continuous process that takes decades to develop, and early detection of HPV can prevent the long-term development of cervical cancer and the unfavourable course of the disease. The aim of the study is an evaluation of the effectiveness of HPV testing as primary screening project of the cervical cancer on the base of University clinic of Odessa National Medical University.

Materials and methods. The results of a project on HPV-testing by the Hybrid Capture technology (digene HC2 HPV DNA Test) of 294 women in the Оdessa were summarized. Results. The frequency of high-risk HPV infection in the studied region was 10.5%, the average viral load was 319.97 RLU / COV ratio in the total sample, which corresponds to a high viral load (more than 3×107 genomic equivalents). In 10.7% of HPV-positive women, cervical pathology was revealed, cervical cancer in the early stages was detected in 28% women (2 cancer in situ and 1 cancer IA). Conclusions. Thus, the introduction of new screening and prevention technologies using simple and standardised methods shows effective results aimed at reducing female morbidity and mortality. The successful experience of the study makes it possible to recommend the introduction of HPV testing at the compulsory stage of medical examination of the population as a more effective screening in terms of clinical and economic aspects.

Key words: cervical cancer, human papillomavirus, HPV- testing, viral load, cervical dysplasia

REFERENCES

  1. Arbyn M., Weiderpass E., Bruni L. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health . 2020 Feb; 8(2): e191–e203.
  2. Bairamova GR, Baranov II, Ezhova LS. et al. Squamous Intraepithelial Cervix Lesions: Possible Early Diagnostics and Management. Doctor.Ru. 2019, 11(166):61–67. DOI:10.31550/1727-2378-2019-166-11-61-67 (in Russian).
  3. Prevention of cervical cancer: a guide for doctors. Sukhikh GТ, Prilepskaya VN. ed. 3rd ed. М.: MEDpress-inform, 2012: 190 (in Russian).
  4. Belokrinitskaya TE, Turanova OV, Frolova NI. Purpose of the study. Evaluate the prognostic value of an independent and medical fence of the vaginal discharge for the HPV test. Gynecology. 2018; 20(2):51–54. doi: 10.26442/2079- 5696_2018.2.51-54 (in Russian).
  5. Turanova OV, Belokrinitskaya TE, Frolova NI. et al. Modern approach to primary cervical cancer screening (literature review). Acta Biomedica Scientifica. 2018; 3(3): 47–53. doi:10.29413/ ABS.2018-3.3.7 (in Russian).
  6. Belokrinitskaya TE, Frolova NI, Turanova OV. et al. Results of human papillomavirus testing on self-collected versus clinician- collected samples. Gynecology. 2017; 19(1): 56–62 (in Russian).
  7. Gregoire L., Lawrence W.D., Kukuruga D. et al. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int. J. Cancer. 1994; 57: 504–507 (in Russian).
  8. Odunsi K, Terry G, Ho L. et al. Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia. Mol. Med. 1995; 1: 161–171 (in Russian).
  9. Wentzensen N, Sun C, Ghosh A. et al. Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. JNCI. 2012;104:1738– 1749 (in Russian).
  10. Lando M, Fjeldbo CS., Wilting SM. et al. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer. Epigenetics. 2015; 10: 970–980 (in Russian).
View article PDF